AnaptysBio, Inc. (ANAB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$55.70-1.59%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
AnaptysBio aims to reach $390 million in Jemperli royalties by 2029. The company recently completed a spin-off to focus on core operations. A new CFO was hired to improve financial management. The stock price has risen over 60% in the last three months, showing renewed investor interest.
AnaptysBio is currently loss-making with negative revenue growth expected this year. Recent earnings missed expectations and management has been volatile. Analysts have cut earnings estimates recently, signaling ongoing challenges.
The market expects about a 24% decline in revenue next year and the stock trades about 26% below our valuation model's midpoint. Our view is more optimistic on the company’s ability to stabilize and grow royalties, but the market remains cautious.
Breaks if: Jemperli royalties fail to grow toward $390 million by 2029
Breaks if: Significant management turnover or failure to execute key initiatives
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently navigating a challenging environment with volatile management and elevated risks, but it has strong recent financial performance and a promising growth trajectory from royalties.
The market appears to price in a low expectations gap, suggesting that investors are not overly optimistic about ANAB's future performance. Valuation is considered cheap compared to peers, indicating that there may be room for improvement if the company can execute on its growth plans.
Fundamentals may face challenges in the near term due to a high probability of an earnings miss, as recent performance has been erratic. However, the company's focus on achieving significant royalty growth from Jemperli and the completion of its spin-off could provide a foundation for future stability.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company is on track to achieve $390 million in Jemperli royalties by 2029. This progress reinforces the thesis around its growth potential. There are no new threats identified that could weaken this outlook.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
AnaptysBio appointed Christopher M. Murphy as the new Chief Financial Officer.
Breaks if: Revenue falls below $390 million in FY26
The thesis hinges on management's ability to maintain guidance and deliver on growth targets, particularly in light of sector performance and economic conditions. Key factors include the performance of sector bellwethers and any potential changes in economic indicators that could affect the healthcare sector.
In the next 1 to 3 years, ANAB's performance will depend on its execution of strategic priorities and external market conditions. Not investment advice.